Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125642 · ClinicalTrials.gov registry record · Phase 2
Auto Stem Cell Transplant for Lymphoma Patients
A Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03125642: Recruiting Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03125642 is a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 150 participants, below the 166-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03125642, a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Primary Outcome
Compare progression-free survival (PFS) at 3 years post-transplant for patients who received who received a radiation free preparative regimen to the prior study MT2004-24 where NHL subjects received total body irradiation (TBI) as part of their preparative regimen.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Etoposide
- DRUG BCNU
- DRUG AraC
- PROCEDURE Peripheral blood stem cell transplantation
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What NCT03125642 shows while recruiting
NCT03125642 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 166-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (10% lower).
The record links to 2 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT03125642 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03125642 about?
NCT03125642 is a clinical study titled "Auto Stem Cell Transplant for Lymphoma Patients". This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
What is the current status of trial NCT03125642?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-04-20. Estimated completion is 2027-04-30.
What conditions does trial NCT03125642 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma.
What interventions are being tested in trial NCT03125642?
The interventions under investigation include: Melphalan (DRUG), Etoposide (DRUG), BCNU (DRUG), AraC (DRUG), Peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03125642?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03125642 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03125642's enrollment target sits among peer trials
150 26th of 106 higher than 80 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI